NL-OMON46547已完成不适用
A phase I, double-blind, randomized, placebo-controlled, multicenter, Single- and multiple-ascending-dose study to determine initial safety, Tolerability, and pharmacokinetics of GDC-0134 in patients with amyotrophic Lateral sclerosis - GN29823 - ALS phase 1
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion criteria for study entry are as follows:
- •* Signed Informed Consent Form
- •* Age * 18 years
- •* Able to comply with the study protocol, in the investigator*s judgment
- •* Male or female participants with a diagnosis of possible, laboratory-supported probable, probable, or definite ALS according to modified El Escorial criteria
- •* For men: agreement to remain abstinent or use a condom during the treatment period and for at least 90 days after the last dose of study drug and agreement to refrain from donating sperm during this same period Men who wish to father a child should consider sperm banking prior to entry into the study.
- •Men with a pregnant partner must agree to remain abstinent or use a condom for the duration of the pregnancy.
- •Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- •* For women who are not postmenopausal (* 12 months of non*therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year, during the treatment period and for at least 28 days after the last dose of study drug
- •Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- •Barrier methods must always be supplemented with the use of a spermicide.
- •Examples of contraceptive methods with a failure rate of < 1% per year include tubal ligation, male sterilization, hormonal implants, established, proper use of combined oral or injected hormonal contraceptives, and certain intrauterine devices.
- •Hormonal contraceptive methods must be supplemented by a barrier method.
- •* Ability to swallow up to 12 capsules with water and ingest approximately 120 mL (4 ounces) of applesauce containing drug suspension within 5 minutes during each dosing period
- •* Upright forced vital capacity of at least 50%
- •* Ability to fast from food for 8 hours prior to dosing and 2 hours after dosing (with exception of OSE participants);Additional OSE Inclusion Criteria
- •* Signed OSE Informed Consent Form
排除标准
- •Patients who meet any of the following criteria will be excluded from study entry:
- •* Pregnant or lactating or intending to become pregnant
- •Women who are not postmenopausal (* 12 months of non*therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 28 days prior to initiation of study drug and a negative urine pregnancy test on Day * 1 (if positive, this should be confirmed with a serum pregnancy test).
- •* Best-corrected visual acuity worse than 20/40 in either eye
- •* History of optic neuropathy
- •* History of optic disc swelling or atrophy
- •* History of intraocular eye disease (e.g., glaucoma, uveitis, diabetic retinopathy)
- •* History of intraocular surgery or retinal laser treatment, with the exception of cataract surgery > 3 months before Day * 1
- •YAG laser capsulotomy is allowed if not within 3 months of Day *1.
- •* Poorly controlled diabetes If there is a medical history of diabetes or if the investigator suspects that diabetes is present, hemoglobin A1C should be reviewed in the patient*s medical record or, if no recent value is available, obtained at screening; a value * 8% constitutes poor control
- •* Presence of cognitive impairment, clinical dementia, or psychiatric illness, or other neurodegenerative disease (e.g., Parkinson*s disease or Alzheimer*s disease) that is significant, in the opinion of the investigator
- •* Currently taking riluzole unless on a stable dose for the 3 months prior to Day -1 and without current liver enzyme or liver function abnormalities. *
- •Currently taking edaravone unless after completion of at least the second 14-day drug-treatment period, as long as Day 1 occurs during a drug-free period at least 24 hours after the last edaravone dose and at least 5 days prior to the first dose of the next cycle.
- •* Currently taking medications with significant risk of producing liver injury (e.g., statins, creatine) unless on a stable dose for the 6 months prior to screening and without a history of liver enzyme or liver function abnormalities
- •* Currently taking nutritional/herbal supplements (except for over-the-counter vitamins that are within
- •Recommended Dietary Allowance [RDA]) or marijuana unless discontinued at least 7 days prior to Day * 1, except upon approval of both the investigator and Sponsor.
- •No new nutritional/herbal supplement may be initiated during the study.
- •* Investigational therapy within 1 month or 5 half-lives, whichever is longer, prior to initiation of study treatment. No investigational therapy may be initiated during the study.
- •* Currently taking anticoagulation medications, including low molecular heparin, non*vitamin K antagonist oral anticoagulants (NOACs), antiplatelet therapy (e.g., Plavix [clopidogrel])
- •Aspirin and other non-steroidal anti-inflammatory drugs are allowed.
- •The use of heparin to maintain patency of intravenous (IV) catheters is allowed, because it is not expected to affect the coagulation status of the patient.
- •* Planned parenteral feeding tube placement during the study
- •* Positive for hepatitis C antibody, hepatitis B surface antigen, or HIV antibody
- •* History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator*s judgment
- •* Serious infection requiring oral or IV antibiotics within 30 days prior to screening
- •* Any medical condition or clinical laboratory result that, in the investigator*s judgme
研究者
相似试验
Unknown
1 期
A phase I clinical trial to study the safety tolerability, pharmacokinetics, food effect and pharmacodynamics of a new compound P7435 in in healthy, overweight and/or obese subjectsCTRI/2012/05/002691Piramal Healthcare Limited96
进行中（未招募）
1 期
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single/multiple doses of IMVT-1402 in healthy participants and participants with autoimmune diseasesISRCTN11659633Immunovant Sciences GmbH168
招募中
不适用
A phase I, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of GDC-6599 and the effect of food on the pharmacokinetics and pharmacodynamics of GDC-6599 in healthy adult subjectsAsthma10024970NL-OMON52277Genentech, Inc.92
招募中
1 期
Phase I Single-Administration Study of TKT001-SHealthy adult malesJPRN-jRCT2071230046Kai Megumi16
已完成
1 期
A study to evaluate the safety, tolerability, processing by the body, and response of the body to the drug VK2735 in healthy adultson-alcoholic steatohepatitis (NASH)Digestive SystemOther specified inflammatory liver diseasesISRCTN47896018Viking Therapeutics, Inc.88